Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
Status:
Completed
Trial end date:
2021-05-19
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine
the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6
(CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of
ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured
via total molybdenum with the coadministration of bupropion.